Department of Pharmacology and Physiology, Georgetown University, Washington, DC.
Department of Biochemistry and Molecular and Cellular Biology, Georgetown University, Washington, DC.
Semin Nephrol. 2021 Jul;41(4):318-330. doi: 10.1016/j.semnephrol.2021.06.004.
Both obesity and chronic kidney disease are increasingly common causes of morbidity and mortality worldwide. Although obesity often co-exists with diabetes and hypertension, it has become clear over the past several decades that obesity is an independent cause of chronic kidney disease, termed obesity-related glomerulopathy. This review defines the attributes of obesity-related glomerulopathy and describes potential pharmacologic interventions. Interventions discussed include peroxisome proliferator-activated receptors, the farnesoid X receptor, the Takeda G-protein-coupled receptor 5, and the vitamin D receptor.
肥胖症和慢性肾脏病在全球范围内都是发病率和死亡率日益增高的主要病因。虽然肥胖症常与糖尿病和高血压并存，但过去几十年的研究已经明确，肥胖症是慢性肾脏病的一个独立病因，被称为肥胖相关性肾小球病。本文对肥胖相关性肾小球病的特征进行了定义，并对潜在的药物干预措施进行了描述。讨论的干预措施包括过氧化物酶体增殖物激活受体、法尼醇 X 受体、Takeda G 蛋白偶联受体 5 和维生素 D 受体。
